Goodman's Centennial 25/26 Season will conclude with programming for all ages, interests and neighborhoods. The theater has unveiled its 4th annual partnership with Chicago Park District’s “Night Out ...

This June has been nothing more than Hunter Goodman proving he's the future of the Colorado Rockies franchise with his continuous power at the plate. As June nears its end, the Colorado Rockies find ...

“I am a world-class alcoholic,” growls Nick Offerman’s Eugene O’Neill. “A tragedy magnet, and by all accounts, the last person on Earth you’d want as your birth doula.” “If someone shushes you, don’t ...

Pat Kelsey and Louisville basketball had one of the best offseasons in college basketball. The Cardinals added elite players from the Transfer Portal and the 2026 recruiting class, landing the ...

The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for Eli Lilly's cancer drug, Jaypirca. In clinical trials, the healthcare giant's once-daily ...

The Lindbergh Baby joke wasn’t working. Not because it was tasteless — you don’t have a Lindbergh Baby joke unless you know it’s tasteless to begin with — but because the joke didn’t land, it wasn’t ...

Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program, CNBC has learned ...

Indianapolis-based Eli Lilly and Company gave an unidentified 79-year-old man exclusive access to its experimental obesity and diabetes drug, according to reporting by the life sciences media ...

The FDA has collaborated with Eli Lilly (LLY) to allow an unidentified 79-year-old man to receive the Indiana-based pharma giant’s next-gen obesity therapy retatrutide, Stat News reported on Tuesday.